A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Gene Therapy

• Publication date

  2007-10-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.gt.3303036PMID 17928874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.

  2006cited by this paper
• The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context

  2006cited by this paper
• A Virosomal Immunization Strategy against Cervical Cancer and Pre-Malignant Cervical Disease

  2006cited by this paper
• Intradermal Delivery of Adenoviral Type-35 Vectors Leads to High Efficiency Transduction of Mature, CD8+ T Cell-Stimulating Skin-Emigrated Dendritic Cells

  2006cited by this paper
• Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia

  2006cited by this paper
• Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice

  2005cited by this paper
• Understanding the generation and function of memory T cell subsets.

  2005cited by this paper
• The papillomavirus life cycle.

  2005cited by this paper
• MyD88 Expression Is Required for Efficient Cross-Presentation of Viral Antigens from Infected Cells

  2005cited by this paper
• Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.

  2004cited by this paper
• Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1

  2004cited by this paper
• Superior Therapeutic Efficacy of Alphavirus-Mediated Immunization against Human Papilloma Virus Type 16 Antigens in a Murine Tumour Model: Effects of the Route of Immunization

  2004cited by this paper
• Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas.

  2004cited by this paper
• Generation and maintenance of immunological memory.

  2004cited by this paper
• Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

  2004cited by this paper
• Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors

  2004cited by this paper
• Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States

  2004cited by this paper
• Cell specificity and efficiency of the Semliki forest virus vector- and adenovirus vector-mediated gene expression in mouse cerebellum.

  2004cited by this paper
• Adenoviruses as vaccine vectors

  2004cited by this paper
• Gene therapy progress and prospects: adenoviral vectors

  2003cited by this paper
• Lineage relationship and protective immunity of memory CD8 T cell subsets

  2003cited by this paper
• Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA.

  2003cited by this paper
• Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

  2003cited by this paper
• Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

  2003cited by this paper
• Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.

  2003cited by this paper
• Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles.

  2003cited by this paper
• A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag 1

  2003cited by this paper
• Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase 1

  2003cited by this paper
• Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination.

  2002cited by this paper
• Human papillomavirus immortalization and transformation functions.

  2002cited by this paper
• The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy.

  2002cited by this paper
• Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7

  2002cited by this paper
• Distinct Roles of Adenovirus Vector-Transduced Dendritic Cells, Myoblasts, and Endothelial Cells in Mediating an Immune Response against a Transgene Product

  2002cited by this paper
• The causal relation between human papillomavirus and cervical cancer.

  2002cited by this paper
• Intravascular adenoviral agents in cancer patients: Lessons from clinical trials

  2002cited by this paper
• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

  2001cited by this paper
• Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens.

  2001cited by this paper
• Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response

  2001cited by this paper
• CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors

  2001cited by this paper
• Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset

  1999cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999cited by this paper
• Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector.

  1999cited by this paper
• Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.

  1999cited by this paper
• Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers

  1998cited by this paper
• A simplified system for generating recombinant adenoviruses.

  1998cited by this paper
• Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

  1996cited by this paper
• Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

  1993cited by this paper

• Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions

  2025cites this paper
• Cancer vaccine strategies using self-replicating RNA viral platforms

  2022cites this paper
• Smart Oncolytic Adenovirotherapy to Induce Killing of Cancer Cells and Elicit Antitumor Immunity

  2022cites this paper
• Semliki Forest virus-based immunotherapy for cancer

  2020cites this paper
• Viral Vector-Based Melanoma Gene Therapy

  2020cites this paper
• First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers

  2020cites this paper
• GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles.

  2020cites this paper
• University of Groningen GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles Jorritsma-Smit,

  2019cites this paper
• Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes

  2019cites this paper
• An alphavirus-based therapeutic cancer vaccine: from design to clinical trial

  2018cites this paper
• Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7 Chapter 6

  2018cites this paper
• Design and delivery strategies of alphavirus replicon-based cervical cancer vaccines

  2018cites this paper
• Immuno-oncology of gynecological malignancies

  2018cites this paper
• TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.

  2017cites this paper
• Oncolytic Alphaviruses in Cancer Immunotherapy

  2017cites this paper
• Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy.

  2017cites this paper
• Viral Vector-Based Cancer Immunotherapy

  2016cites this paper
• A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development

  2015cites this paper
• Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines

  2015cites this paper
• Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7

  2015cites this paper
• Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication

  2015cites this paper
• A candidate therapeutic vaccine against hepatitis C virus infection

  2014cites this paper
• Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination

  2014cites this paper
• Therapeutic vaccination against chronic hepatitis C virus infection.

  2012cites this paper
• Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon

  2012cites this paper
• Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.

  2011cites this paper
• The genetics of alphaviruses

  2011cites this paper
• Alphavirus-based therapeutic immunization against cervical neoplasia

  2011cites this paper
• Role of Regulatory T-Cells in Immunization Strategies Involving a Recombinant Alphavirus Vector System

  2011cites this paper
• From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors

  2011cites this paper
• Immunotherapy for Cervical Cancer

  2010cites this paper
• CD4+ and CD8+ T Cells Can Act Separately in Tumour Rejection after Immunization with Murine Pneumotropic Virus Chimeric Her2/neu Virus-Like Particles

  2010cites this paper
• Alphavirus vectors for cancer therapy.

  2010cites this paper
• Human Papillomavirus-Specific Immune Therapy: Failure and Hope

  2010cites this paper
• Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations

  2010cites this paper
• Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.

  2009cites this paper
• Novel immunotherapeutic strategies for gynaecologic malignancies

  2008cites this paper
• Therapeutic and prophylactic applications of alphavirus vectors

  2008cites this paper